Benzoylphenylurea in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignancy
• * Metastatic or unresectable
• * No effective standard curative or palliative measures exist
• No known CNS or brain metastasis
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin normal
• SGOT/SGPT normal
• Renal:
• Creatinine normal
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No uncontrolled ventricular arrhythmia
• No myocardial infarction within the past 3 months
• No superior vena cava syndrome
• Neurologic:
• No grade 1 or greater peripheral neuropathy
• No uncontrolled major seizure disorder
• No spinal cord compression
• Other:
• No active serious infection requiring IV antibiotics
• No concurrent uncontrolled illness
• No concurrent unstable or serious medical condition
• No chronic diarrhea or malabsorption
• No history of allergic reactions to compounds similar in chemical or biological composition to benzoylphenylurea
• No psychiatric illness or social situation that would preclude study compliance
• Not pregnant or nursing
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent immunotherapy
• No concurrent growth factors during first 2 courses of study
• Concurrent epoetin alfa allowed
• Chemotherapy:
• At least 28 days since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No other concurrent chemotherapy
• Endocrine therapy:
• No concurrent hormonal therapy
• Radiotherapy:
• At least 28 days since prior large-field radiotherapy
• Prior palliative radiotherapy for painful bone metastases allowed
• No concurrent radiotherapy, including palliative or whole-brain radiotherapy for CNS disease
• Surgery:
• At least 28 days since prior major surgery
• Other:
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational or commercial agents or therapies for the malignancy
• No other concurrent investigational agents
• Concurrent bisphosphonates allowed if bone metastases are not only site of measurable or evaluable disease